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Allelic loss at chromosome 9q31–34 is a frequent event in many lymphoproliferative malignancies. Here, we
examined DBC1 at 9q33.1 as a potential target in lymphomagenesis. DBC1 is a putative tumor suppressor that
has been shown to be involved in the regulation of cell growth and programmed cell death. The methylation
status of the DBC1 promoter CpG island was examined by methylation-specific PCR, bisulfite sequencing, and
methylation-specific melting curve analysis. DBC1 was hypermethylated in 5 of 5 B-cell-derived lymphoma cell
lines, 41 of 42 diffuse large B-cell lymphomas, 24 of 24 follicular lymphomas, 5 of 5 mantle cell lymphomas, 4 of
4 small lymphocytic lymphomas, 1 of 2 lymphoplasmacytoid lymphomas, and in 12 of 12 acute lymphoblastic
leukemias, but was unmethylated in 1 case of splenic marginal zone lymphoma, in 12 of 12 multiple myelomas,
in 24 of 24 reactive lymph nodes, and in 12 of 12 samples of blood lymphocytes from random donors. DBC1
hypermethylation was associated with transcriptional silencing in lymphoma cell lines, and reexpression of
this gene could be induced by treatment with the demethylating agent, 5-aza-20-deoxycytidine. Our data suggest
that hypermethylation of the DBC1 promoter region is a frequent event during the development of
lymphoproliferative malignancies, and that DBC1 hypermethylation may serve as a marker for these cancers.
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Loss of heterozygosity (LOH) at the long arm
of chromosome 9 has been demonstrated in
several types of lymphoid malignancies, including
diffuse large B-cell lymphoma,1–3 follicular lympho-
ma,4 multiple myeloma,5 mantle cell lymphoma,6
Hodgkin lymphoma,7 acute lymphoblastic leukemia,8,9
and chronic lymphocytic leukemia.10 Some of these
studies have implicated the 9q32–33 region as the
prevailing target for deletion, suggesting that this
region harbors an important tumor suppressor gene
for lymphoproliferative cancers. The same region
is lost in several other types of human cancers11
with particularly high frequencies reported for
transitional cell carcinomas of the bladder.12
Fine mapping analysis in bladder cancer led to the
identification of a putative tumor suppressor gene at
9q33.1, which has been designated as DBC1 (deleted
in bladder cancer 1).13 The 50 region of DBC1
contains a CpG island that is aberrantly hyper-
methylated in approximately 50% of bladder cancer
cell lines and tumors,13,14 40% of oral squamous cell
carcinomas,15 80% of non-small cell lung cancer
cell lines, and a proportion of primary non-small
cell lung cancer tumors.16 In bladder cancer, low-
density DBC1 promoter methylation was shown to
occur in an age-related manner in the matched
normal tissue, indicating that DBC1 promoter
methylation may constitute an early event in
carcinogenesis.13,14
In humans, DBC1 is expressed at high levels in the
brain and spinal cord13 as well as in mesenchymal
stem cells.17 In a previous study, we have shown
that DBC1 is silenced by promoter methylation
in spontaneously transformed hTERT-transduced
mesenchymal stem cells (TERT-20 cells),
lending further support to a tumor-suppressive role
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of DBC1.17 Notably, DBC1 hypermethylation oc-
curred after loss of the INK4A/ARF locus in these
cells, and silencing of DBC1 was associated with the
ability to form tumors in mice. However, the DBC1-
regulated molecular pathway(s) that exerts a tumor-
suppressive effect in stem cells, and possibly other
cell types, has not yet been fully elucidated. The
protein structure of DBC1 shows some resemblance
to perforin (the membrane-attack complex; amino
acids 72–251), suggesting that DBC1 may be in-
volved in pore formation during cell lysis. Interest-
ingly, perforin has been shown to be involved in
both familial hemophagocytic lymphohistiocytosis18
and sporadic lymphoma by point mutations.19
Ectopic reexpression of DBC1 in cancer cell
lines with DBC1 hypermethylation elicited a range
of cellular effects, including cell-cycle arrest,
caspase-independent apoptosis,20 and altered ex-
pression of key factors in the plasminogen
pathway.21 However, it is still not evident which of
these DBC1 functions are essential in controlling
carcinogenesis, and under which cellular circum-
stances they are active.
Here, we have examined DBC1 as a candidate
tumor suppressor in lymphoid tumors. We show
that the DBC1 50 CpG-island is unmethylated in
normal blood lymphocytes and reactive lymph
nodes, but hypermethylated in 91 of 92 cases of
diffuse large B-cell lymphoma, follicular lymphoma,
mantle cell lymphoma, small lymphocytic lympho-
ma, acute lymphoblastic leukemia and lymphoma
cell lines, and in 1 of 2 cases of lymphoplasmacytoid
lymphoma, suggesting that inactivation of DBC1
is a frequent event in lymphomagenesis. Tran-
scription from a hypermethylated DBC1 promoter
in lymphoma cell lines could be induced by




Lymphoma biopsies were obtained from 42 cases of
diffuse large B-cell lymphoma and 24 cases
of follicular lymphoma, including 12 de novo and
12 relapsed cases, 5 cases of mantle cell lymphoma,
4 cases of small lymphocytic lymphoma, 2 cases
of lymphoplasmacytoid lymphomas and 1 case of
splenic marginal zone lymphoma. Bone marrow
specimens were sampled from 12 cases of multiple
myeloma, and 12 cases of acute lymphoblastic
leukemia, including 7 pre-B-acute lymphoblastic
leukemias and 5 T-acute lymphoblastic leukemias.
Reactive lymph nodes were obtained from 24
individuals, and peripheral blood lymphocytes
were obtained from 12 random, anonymous donors.
RNA from normal human brain was purchased
from Ambion. Approval of this study was obtained
from the local ethical committees.
Cell Culture and 5-aza-20-Deoxycytidine Treatment
Diffuse large B-cell-derived lymphoma cell lines,
Farage, Pfeiffer, DB1, HT, and RL, were purchased
from the American Type Culture Collection (ATCC),
and maintained in RPMI 1640 medium with Gluta-
max supplemented with 10% fetal calf serum. Cells
were treated for 72 h with 5-aza-20-deoxycytidine at
a final concentration of 0.5 mM.
Reverse Transcriptase Polymerase Chain Reaction
RNA from cell lines, reactive lymph nodes and
primary lymphoma samples was extracted using the
NucleoSpin Kit (Macherey-Nagel). One microgram
of RNA was reverse transcribed using Superscript III
(Invitrogen) and subsequently amplified by PCR
using previously described primers.13 Quantitative
PCR was performed using the LightCycler 1.0
instrument (Roche) in 10-ml volumes containing
1ml of cDNA, 5 pmol of each primer, 3 mM MgCl2
and 1FastStart DNA Master SYBR Green I Kit
(Roche). PCR conditions were 10 min at 951C to
activate the enzyme followed by 35 cycles of
denaturation at 951C for 5 s, primer annealing at
651C for 10 s and primer elongation at 721C for 15 s.
Primers for DBC1 amplification were as described.13
GAPDH primers, AGGGGGGAGCCAAAAGGG
(sense) and GAGGAGTGGGTGTCGCTGTTG (anti-
sense) were used for normalization. RNA from
normal brain and early passage TERT-20 cells was
used as positive control; RNA from late passage
TERT-20 cells was used as negative control.
Allelic Loss of DBC1
Genomic DNA was extracted according to standard
procedures. Allelic loss at the DBC1 locus was
identified by analysis of the c.618C/T biallelic
polymorphism in exon 5 of DBC1, using a combina-
tion of PCR and denaturing gradient gel electrophor-
esis (DGGE).22 The primers were: 50-[CGCCCGCCGC
GCCCCGCGCCCGTCCCGCCGCCCCCGCCCG]-TCTC
ACACCTATCTTATTTGATATCTAC-30 and 50-[CCCG
CC]-ACTTTTTCCACTGGCTTCCT-30. PCR was per-
formed in 15-ml reactions containing 10 mm Tris-HCl
(pH 9.0), 50 mM KCl, 1.5 mM MgCl2, 0.2 mM cresol
red, 12% sucrose, 10 pmol of each primer, 100 mM
each dNTP, 100 ng of DNA, and 0.8 units of
HotstarTaq polymerase. The cycling parameters
were: 35 cycles at 951C (20 s), 551C (20 s), and 721C
(30 s). PCR products were analyzed in a 10%
denaturant/6% polyacrylamide-70% denaturant/
12% polyacrylamide double-gradient gel (100%
denaturant¼ 7 M urea and 40% formamide). The
gel was run at 80 V for 16 h in 1TAE buffer kept
at a constant temperature of 561C. In informative
cases, a semi-quantitative estimation of allelic loss
was done by evaluating the intensities of the
two homoduplex bands. After ethidium bromide
DBC1 hypermethylation in lymphoid malignancies
K Grønbæk et al
633
Modern Pathology (2008) 21, 632–638
staining and UV transillumination, a TIFF-format
image of the gel was generated and analyzed using
the 1D Gel Analysis Phoretix Software (Phoretix,
Newcastle, UK).
Promoter Hypermethylation of DBC1
The methylation status of the DBC1 promoter
was examined using three different approaches:
methylation-specific PCR (MS-PCR),23 methylation-
specific melting curve analysis (MS-MCA)24 and
bisulfite genomic sequencing.25 For all three meth-
ods, DNA was treated with sodium bisulfite, which
converts unmethylated cytosine to uracil but leaves
methylated cytosines unchanged.26 MS-PCR was
performed using previously described primers and
conditions.15
For MS-MCA, two primer sets were used. The first
set (50-GTGGGAATTTGGGAGAGTTTT-30 and 50-AA
TATAAACCAAACTACTAAAAACCAAATA-30) ampli-
fies a 100-bp region (including 7 CpG sites) of
the DBC1 50CpG island (nt. þ 41 to nt. þ 140 from
the initiation ATG site), and the other set (50-TAAA
TAGTGTTAAATATTTATAGAGAGA-30 and 50-CCC
AAATCCTAATACCCTTAAA-30) amplifies a 182-bp
region (including 13 CpG sites) from nt. 710 to nt.
528 (GenBank Accession no. NT_008470).
Amplification was carried out using the Light-
Cycler 1.0 instrument (Roche) in 10-ml volumes
containing 1ml of the bisulfite-treated DNA, 5 pmol
of each primer, 3 mM MgCl2 and 1FastStart DNA
Master SYBR Green I Kit (Roche). PCR conditions
were 10 min at 951C to activate the enzyme followed
by 35 cycles of denaturation at 951C for 5 s, primer
annealing at 621C for 10 s and primer elongation at
721C for 15 s. Subsequently, melting curves were
obtained by measuring the drop in fluorescence
when raising the temperature from 70 to 981C at
0.051C/s. The melting peaks were calculated using
the LightCycler software 4.05 as described.24
For bisulfite genomic sequencing, nucleotides
771 to 528 of DBC1 were amplified from
bisulfite-reacted DNA using the primers 50-AGAGA
AGTTTTTGTTTTATTTTG-30 and 50-CCCAAATCCT
AATACCCTTAAA-30. Direct sequence analysis of
PCR products was performed with a 33P-end-labeled
internal primer 50-TGTTTTATTTTGGGAGGTT-30
using the ThermoPrime Cycle Sequencing Kit
(Amersham Life Science, Cleveland, OH, USA),
according to the manufacturer’s instructions.
Results
Allelic Loss of DBC1 in Diffuse Large B-Cell
Lymphoma
To investigate whether deletions of the 9q33 region
in lymphoid neoplasms include DBC1, we examined
a single-base polymorphism in exon 5 of this gene.
Fourteen of 30 diffuse large B-cell lymphomas were
heterozygous for this marker, which allowed us to
evaluate allelic losses in these tumors by resolving
the two alleles by DGGE and measuring the band
intensities. Four of the tumors (29%) showed
unequal allelic distribution, suggesting that one of
the DBC1 alleles had been lost in the tumor cells
(Figure 1).
DBC1 Promoter Hypermethylation in
Lymphoproliferative Malignancies
To examine the methylation status of DBC1 in
lymphoid malignancies, we first examined 12
diffuse large B-cell lymphomas using MS-PCR.
Bisulfite-treated DNA was used as template in two
separate reactions with primers that specifically
amplify either methylated or unmethylated DBC1.
Positive signals for both methylated and unmethy-
lated DBC1 were obtained for all 12 samples
(See Figure 2 for examples).
To exclude potential methodological artifacts, the
same samples were examined using MS-MCA. First,
a region of the DBC1 50 CpG-island containing 7 CpG
sites was amplified from bisulfite-treated DNA using
primers that do not discriminate between methy-
lated and unmethylated molecules, and the PCR
products were subsequently subjected to melting
analysis. In concordance with the results of the
Figure 1 DGGE-based detection of DBC1 allelic loss. Diffuse large
B-cell lymphoma (DLBCL) no. 111 shows loss of one of the alleles
of the c.618C/T polymorphism. Pixel intensity and gel distance
are in arbitrary units.
Figure 2 MS-PCR analysis of the DBC1 promoter in diffuse large
B-cell lymphoma. DNA was treated with sodium bisulfite and
PCR-amplified with primer pairs specific for unmethylated (lanes
U) and methylated (lanes M) DBC1 alleles. SssI-methylated DNA
provided a positive and peripheral blood lymphocytes (PBL) a
negative control for methylated DBC1.
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MS-PCR analysis, all diffuse large B-cell lymphomas
showed a peak with an apparent melting tempera-
ture (Tm) of approximately 841C, corresponding to
the peak obtained with SssI-methylated DNA,
whereas peripheral blood lymphocytes showed a
single melting peak with a Tm~41C lower (Figure 3a).
Most diffuse large B-cell lymphomas also showed
the lower-melting peak, probably originating from
non-malignant cells in these samples.
Next we used the MS-PCR and MS-MCA assays to
examine the methylation status of DBC1 in a broader
spectrum of lymphoid neoplasms, including 30
additional diffuse large B-cell lymphomas, 12
primary follicular lymphomas, 12 relapsed follicular
lymphomas, 5 mantle cell lymphomas, 4 small
lymphocytic lymphomas, 2 lymphoplasmacytoid
lymphomas, 1 splenic marginal zone lymphoma,
12 acute lymphoblastic leukemias, 12 multiple
myelomas, and 5 cell lines (Farage, Pfeiffer, DB1,
HT, and RL) that were established from patients
with diffuse large B-cell lymphoma. In total, DBC1
hypermethylation was detected in 41 of the diffuse
large B-cell lymphomas (98%), 24 of the follicular
lymphomas (100%), 5 of the mantle cell lymphomas
(100%), 12 of the acute lymphoblastic leukemias
(100%), 4 of the small lymphocytic lymphomas
(100%), 1 of the lymphoplasmacytoid lymphomas
(50%) and 5 of the cell lines (100%) (Table 1).
Three of the small lymphocytic lymphomas and
the methylated lymphoplasmacytoid lymphoma
showed a single melting peak with a melting
temperature between the peaks for fully methylated
and unmethylated DNA, suggesting that the promo-
ter was heterogeneously methylated in these cases.
The cell lines contained only hypermethylated
DBC1 alleles (data not shown), suggesting that the
methylation is either biallelic or monoallelic in
combination with loss of the other DBC1 allele. All
12 multiple myelomas and the case of splenic
marginal zone lymphoma contained only unmethy-
lated DBC1 (Table 1).
Recently, the activity of the DBC1 promoter was
suggested to be associated with the methylation
status of a region upstream of the sequence exam-
ined in our first experiments.16 We, therefore, also
examined the methylation status of this region by
MS-MCA and bisufite genomic sequencing. All five
lymphoma cell lines and six of seven diffuse large
B-cell lymphomas, which all showed a fully methy-
lated proximal promoter region, were also fully
methylated in the distal part of the promoter (Figure
3b). The remaining diffuse large B-cell lymphoma
showed heterogeneous methylation of the distal part
of the DBC1 promoter. Similar to the analysis of the
proximal part of the promoter, most of the primary
diffuse large B-cell lymphomas also showed a low-
melting peak corresponding to unmethylated DBC1.
Bisulfite genomic sequencing of the distal part of the
promoter in the five lymphoma cell lines and in
normal and fully methylated controls confirmed the
MS-MCA data (Figure 3c).
To examine the possible correlation between
promoter hypermethylation and transcriptional
silencing, as has been demonstrated for a great
number of tumor suppressor genes,27 we analyzed
RNA from 12 primary diffuse large B-cell lympho-
mas using real-time quantitative RT-PCR. As posi-
tive controls, we used RNA from human brain and
TERT-20 cells.28 These cells express DBC1 at early
passages, but lack expression at later passages.17
Using this PCR assay, which easily detected RNA
from TERT-20 cells diluted 1000-fold, we were
Figure 3 Methylation analysis of the DBC1 promoter in diffuse
large B-cell lymphoma and lymphoma cell lines. Examples of
MS-MCA are shown for the proximal (a) and distal (b) part of
the promoter. (c) Bisulfite genomic sequencing of the distal part
of the DBC1 promoter. CpG sites are indicated by asterisks.
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unable to detect DBC1 transcripts in any of the
primary lymphoma samples (data not shown).
DBC1 is Unmethylated in Normal Peripheral Blood
Lymphocytes and Reactive Lymph Nodes
To examine whether DBC1 promoter hypermethyla-
tion was specific for malignant lymphoid cells, we
first examined peripheral blood lymphocytes from
12 random donors. Both the MS-PCR and MS-MCA
assays generated only signals for unmethylated
DBC1. We also examined DNA isolated from 24
reactive lymph nodes, which were removed because
of suspected malignancy. These specimens included
uninvolved lymph nodes from patients with
malignant melanoma, and reactive lymph nodes
from patients with infectious diseases or chronic
inflammation. Eight of these lymph nodes showed a
remarkable follicular hyperplasia that, by histology,
could be misinterpreted as follicular lymphoma.
None of the 24 reactive lymph nodes showed
any evidence of aberrant DBC1 methylation, as
determined by MS-PCR and MS-MCA (Table 1).
We also examined the expression of DBC1 in
seven reactive lymph nodes and in six peripheral
blood lymphocyte samples from normal donors.
None of these peripheral blood lymphocytes or
lymph nodes showed expression of DBC1 mRNA
by RT-PCR or real-time quantitative PCR analysis
(data not shown). Thus, considering that the DBC1
promoter is unmethylated in peripheral blood
lymphocytes (Figures 2 and 3) and reactive lymph
nodes, DBC1 expression may be blocked in normal
lymphocytic cells by a methylation-independent
mechanism.
Reexpression of DBC1 in Lymphoma Cell Lines
To examine whether promoter methylation of DBC1
is required to suppress transcription in lymphoma
cells, we treated five cell lines with the demethylat-
ing agent, 50-aza-2-deoxycytidine. None of the
untreated cell lines expressed DBC1 mRNA, but
expression was activated in all cell lines after
treatment with 50-aza-2-deoxycytidine (Figure 4).
These data indicate that demethylation of the DBC1
promoter may be sufficient to induce DBC1 expres-
sion in lymphoma cells and, accordingly, that the
factor(s) suppressing DBC1 expression in normal
lymphocytes is lost in the malignant counterparts.
DBC1 Hypermethylation in Lymphoid Malignancies
is Age Independent
Previous studies have shown that promoter CpG
islands of some tumor suppressor genes can become
hypermethylated in an age-dependent manner.29
Specifically, hypermethylation of the DBC1 promo-
ter has been demonstrated in normal urothelium
from men 450 years old.14 Since the incidence of
lymphoma is increasing with age and is highest
among individuals aged 460 years,30 we considered
whether a similar age-related mechanism might
explain the high frequency of DBC1 hypermethyla-
tion in lymphoproliferative malignancies. However,
the lymphoma and acute lymphoblastic leukemia
patients harboring DBC1 hypermethylation in their
tumors showed a wide age distribution, with 410%






Number of cases with
DBC1 hypermethylation
Lymphoma cell lines 5 NA 5 (100%)
Diffuse large B-cell lymphoma 42 65 (26–94) 41 (98%)
Follicular lymphoma 24 49 (33–80) 24 (100%)
Acute lymphoblastic leukemia 12 22 (7–63) 12 (100%)
Mantle cell lymphoma 5 66 (59–86) 5 (100%)
Small lymphocytic lymphoma 4 58 (47–84) 4 (100%)
Lymphoplasmacytoid lymphoma 2 50/81 1 (50%)
Multiple myeloma 12 58 (41–77) 0 (0%)
Reactive lymph nodes 12 28 (18–41) 0 (0%)
12 70 (56–78) 0 (0%)
Peripheral blood lymphocytes 12 NA 0 (0%)
NA, not available.
Figure 4 DBC1 expression in lymphoma cell lines. RT-PCR
analysis of a 232-bp DBC1 transcript (exons 7–8) in lymphoma
cells lines with and without treatment with 5-aza-20-deoxycyti-
dine (Aza; 0.5 mM) for 3 days. Early and late passage TERT-20 cells
were used as positive and negative controls, respectively.
Amplification of GAPDH transcripts is shown as a control for
RNA quality. L, 100-bp ladder.
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of the lymphoma patients and 480% of the
acute lymphoblastic leukemia patients aged o40
years. Furthermore, DBC1 hypermethylation was
not detected in multiple myeloma patients aged up
to 77 years or in reactive lymph nodes from a
group of 12 elderly (median 70 years; range
56–78). These data suggest that DBC1 hypermethy-
lation in lymphoma is cancer specific and occurs
independent of age.
Discussion
Here, we have shown that the DBC1 promoter is
hypermethylated in lymphoma cell lines and in
virtually all cases of diffuse large B-cell lymphoma,
follicular lymphoma, mantle cell lymphoma, small
lymphocytic lymphomas, acute lymphoblastic leu-
kemia, and in a fraction of lymphoplasmacytoid
lymphomas, but not in multiple myeloma speci-
mens, reactive lymph nodes, or peripheral blood
lymphocytes from healthy individuals. In addition,
allelic loss of DBC1 was found in roughly one-third
of diffuse large B-cell lymphomas. Collectively,
these data suggest that inactivation of DBC1 by
promoter hypermethylation and/or deletion is
an almost obligate event in diffuse large B-cell
lymphoma, follicular lymphoma, mantle cell
lymphoma, small lymphocytic lymphoma, and
acute lymphoblastic leukemia. Using MS-PCR, San
Jose´-Ene´riz et al31 recently demonstrated DBC1
hypermethylation in 29/141 acute lymphoblastic
leukemias and 4/4 acute lymphoblastic leukemia
cell lines.
A direct role of DBC1 as a tumor suppressor has
been questioned because its expression is sup-
pressed in most normal human cells, with brain
tissue,13 lung,16 and early passage mesenchymal
stem cells17 as notable exceptions. Recent transfec-
tion studies with full length DBC1 in a bladder
cancer cell line showed inhibition of population
growth, but no increases in cell death.21 However,
other attempts to generate cells with stable DBC1
expression have repeatedly failed, indicating that
expression of DBC1 may lead to severe growth
inhibition or even cell death, at least in some
cellular contexts. Indeed, Wright et al20 showed that
induced expression of DBC1 in bladder tumor
cell lines induced caspase-independent cell death.
Accordingly, activation of DBC1 expression may be
important for the elimination of some normal cells,
possibly acting as a fail-safe mechanism that is
triggered in parallel with other death pathways or
when other death pathways fail.
Several other tumor suppressor genes have been
shown to be hypermethylated in lymphoma,
although the prevalence of hypermethylation for
individual tumor suppressor genes rarely exceeds
60%.32 However, Reddy et al33 recently showed that
the SHP1 promoter region is almost universally
methylated in lymphomas and leukemias. Methylation
frequencies at or close to 100% have also been
reported for a set of genes involved in B-cell
signaling in Hodgkin disease.34
According to the current paradigm, hypermethy-
lation of tumor suppressor genes is acquired earlier
or later in the tumorigenic process. Nevertheless,
considering that hypermethylation of the DBC1
promoter occurred in almost 100% of diffuse large
B-cell lymphoma, follicular lymphoma, mantle cell
lymphoma, small lymphocytic lymphoma, and
acute lymphoblastic leukemia, we cannot exclude
that DBC1 hypermethylation may be an inherent
epigenetic feature of the cells from which these
tumors are derived. The cellular origin of the
individual lymphoid malignancies is still unknown,
although the present lymphoma classification is
based on the assignment of tumors to their
presumed normal counterparts in the normal lym-
phocyte differentiation pathways. Other theories
suggest that cancers may originate from a common
population of epigenetically marked stem or progeni-
tor cells. In early cell differentiation, when methyla-
tion fluctuates, non-neoplastic stem or progenitor cells
may achieve specific growth or survival advantages by
the particular epigenetic signature.35,36 This expanded
population of epigenetically altered, yet polyclonal
progenitor cells may thus have obtained an oncogenic
potential that makes them more vulnerable to second-
ary tumorigenic events.
Whether DBC1 promoter hypermethylation is
acquired during lymphomagenesis or is a normal
epigenetic characteristic of certain hematologic
precursor cells, it may serve as a marker to
discriminate between benign lymphoid hyperplasia
and malignant lymphoproliferation. While a nega-
tive DBC1 methylation test does not exclude
malignancy and will require further analysis, a
lymph node that is positive for DBC1 methylation
is likely to represent malignancy. If indeed DBC1 is a
tumor suppressor that is important in the control of
lymphopoiesis, DBC1 may be a potential target for
lymphoma treatment since transcriptional silencing
by DNA methylation can be reversible controlled by
inhibitors of methylation.37
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